In Q2 2018, ISR surveyed drug innovators who outsource bioprocessing / biologic API manufacturing to learn their thoughts on what will have the greatest impact on biologics market growth over the next five years. The data show that roughly one-fifth of respondents believe that new technologies and/or process improvements will catalyze the most growth.

Originally published at Bioprocess Online.

View File